Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. Show more
Location: 1800 Sierra Point Parkway, Suite 217, Brisbane, CA, 94005, United States | Website: https://dayonebio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
648.7M
52 Wk Range
$6.08 - $16.76
Previous Close
$6.50
Open
$6.58
Volume
1,872,363
Day Range
$6.32 - $6.62
Enterprise Value
188.8M
Cash
473M
Avg Qtr Burn
-21.85M
Insider Ownership
17.03%
Institutional Own.
94.47%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OJEMDA™ (Tovorafenib) (DAY101) Details Cancer, Pediatric low-grade glioma | Approved Quarterly sales | |
OJEMDA™ (Tovorafenib) (DAY101) Details Cancer, Pediatric low-grade glioma | Phase 3 Update | |
DAY301 (formerly MTX-13) Details Solid tumor/s | Phase 1 Data readout | |
Tovorafenib (DAY101) +/- Pimasertib Details Solid tumor/s, Cancer | Failed Discontinued |